Recent data reveals that retatrutide, a dual-action medication, could represent a major improvement in weight management. This therapy combines the properties of a GLP-1 analog and a GIP receptor , potentially offering a enhanced impact than available approaches . Patient trials have demonstrated promising outcomes, including substantial decreases